Syndax Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US87164F1057

SecuritySNDX / Syndax Pharmaceuticals, Inc.
InstitutionCwm, Llc
Latest Disclosed Ownership37,046 shares
Latest Disclosed Value $ 865,395
Cwm, Llc reports 16.09% increase in ownership of SNDX / Syndax Pharmaceuticals, Inc.

On May 14, 2026 - Cwm, Llc filed a 13F-HR form disclosing ownership of 37,046 shares of Syndax Pharmaceuticals, Inc. (US:SNDX) valued at $865,395 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 26, 2026 disclosing 31,912 shares of Syndax Pharmaceuticals, Inc.. The current value of the position is $642,378 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F SYNDAX PHARMACEUTICALS COM 87164F105 37,046 5,134 16.09 865 0.0022
2026-01-26 2025-12-31 13F SYNDAX PHARMACEUTICALS COM 87164F105 31,912 10,737 50.71 1 0.0018
2025-10-15 2025-09-30 13F SYNDAX PHARMACEUTICALS COM 87164F105 21,175 12,414 141.70 0 0.0010
2025-07-25 2025-06-30 13F SYNDAX PHARMACEUTICALS COM 87164F105 8,761 -14,613 -62.52 0 0.0003
2025-05-01 2025-03-31 13F SYNDAX PHARMACEUTICALS COM 87164F105 23,374 20,763 795.21 0 0.0011
2025-02-04 2024-12-31 13F SYNDAX PHARMACEUTICALS COM 87164F105 2,611 855 48.69 0 0.0001
2024-10-08 2024-09-30 13F SYNDAX PHARMACEUTICALS COM 87164F105 1,756 54 3.17 0 0.0001
2024-07-10 2024-06-30 13F SYNDAX PHARMACEUTICALS COM 87164F105 1,702 -22 -1.28 0 0.0002
2024-04-05 2024-03-31 13F SYNDAX PHARMACEUTICALS COM 87164F105 1,724 39 2.31 0 0.0002
2024-02-01 2023-12-31 13F SYNDAX PHARMACEUTICALS COM 87164F105 1,685 1,358 415.29 0 0.0002
2023-10-11 2023-09-30 13F SYNDAX PHARMACEUTICALS COM 87164F105 327 -266 -44.86 0 0.0000
2023-08-03 2023-06-30 13F SYNDAX PHARMACEUTICALS COM 87164F105 593 586 8,371.43 0 0.0001
2023-05-01 2023-03-31 13F SYNDAX PHARMACEUTICALS COM 87164F105 7 7 0 0.0000
2020-10-19 2020-09-30 13F SYNDAX PHARMACEUTICALS COM 87164F105 0 -200 -100.00 0 -100.00
2020-07-22 2020-06-30 13F SYNDAX PHARMACEUTICALS COM 87164F105 200 200 3 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.